Geron Corp (NASDAQ:GERN) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $240 thousand. The company also announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on Geron’s investigational new drug (IND) application for imetelstat. In addition, the FDA stated that Geron’s … Continue reading Moving Stocks: Geron Corporation (NASDAQ:GERN), Alcatel Lucent SA (ADR) (NYSE:ALU), CenterState Banks, Inc. (NASDAQ:CSFL), Highpower International, Inc. (NASDAQ:HPJ), Ensco plc (NYSE:ESV)